# ProShares Trust II: financial statements, quarterly

AGQ · NYSE · CIK 1415311 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/agq.md) · [Financials](/companies/agq/financials.md) · [Filings](/companies/agq/filings.md) · [Insiders](/companies/agq/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/agq/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | [31.0](/filings/0001193125-26-214433.md) | [31.6](/filings/0001193125-26-340159.md) | not reported | not reported | [44.6](/filings/0001193125-26-214433.md) | [49.7](/filings/0001193125-26-340159.md) |
| Net income | $m | [(12.0)](/filings/0001193125-24-261004.md) | [(730) d](/filings/0001193125-26-077441.md) | [(232)](/filings/0001193125-25-116684.md) | [240](/filings/0001193125-25-176892.md) | [(11.7)](/filings/0001193125-25-272134.md) | [(36.3) d](/filings/0001193125-26-077441.md) | [428](/filings/0001193125-26-214433.md) | [171](/filings/0001193125-26-340159.md) | [76.1](/filings/0001193125-25-272134.md) | [1,037 d](/filings/0001193125-26-077441.md) | [478](/filings/0001193125-26-214433.md) | [(1,202)](/filings/0001193125-26-340159.md) |

- Revenue: us-gaap:Revenues
- Net income: us-gaap:NetIncomeLoss

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [367](/filings/0001193125-23-271363.md) | [1,209](/filings/0001193125-25-039791.md) | [687](/filings/0001193125-24-260994.md) | [822](/filings/0001193125-24-261001.md) | [1,000](/filings/0001193125-24-261004.md) | [1,766](/filings/0001193125-26-077441.md) | [1,311](/filings/0001193125-25-116684.md) | [2,207](/filings/0001193125-25-176892.md) | [915](/filings/0001193125-25-272134.md) | [2,000](/filings/0001193125-26-340159.md) | [801](/filings/0001193125-26-214433.md) | [505](/filings/0001193125-26-340159.md) |
| Total assets | $m | [3,400](/filings/0001193125-23-271363.md) | [3,370](/filings/0001193125-25-039791.md) | [3,136](/filings/0001193125-24-260994.md) | [3,308](/filings/0001193125-24-261001.md) | [3,579](/filings/0001193125-24-261004.md) | [3,152](/filings/0001193125-26-077441.md) | [3,739](/filings/0001193125-25-116684.md) | [3,808](/filings/0001193125-25-176892.md) | [4,622](/filings/0001193125-25-272134.md) | [6,063](/filings/0001193125-26-340159.md) | [6,535](/filings/0001193125-26-214433.md) | [4,889](/filings/0001193125-26-340159.md) |
| Total liabilities | $m | [100.0](/filings/0001193125-23-271363.md) | [87.4](/filings/0001193125-25-039791.md) | [47.5](/filings/0001193125-24-260994.md) | [187](/filings/0001193125-24-261001.md) | [110](/filings/0001193125-24-261004.md) | [127](/filings/0001193125-26-077441.md) | [165](/filings/0001193125-25-116684.md) | [156](/filings/0001193125-25-176892.md) | [101](/filings/0001193125-25-272134.md) | [339](/filings/0001193125-26-340159.md) | [349](/filings/0001193125-26-214433.md) | [324](/filings/0001193125-26-340159.md) |
| Shareholders' equity | $m | [3,300](/filings/0001193125-24-261004.md) | [3,283](/filings/0001193125-26-077441.md) | [3,089](/filings/0001193125-25-176892.md) | [3,121](/filings/0001193125-25-272134.md) | [3,469](/filings/0001193125-25-272134.md) | [3,025](/filings/0001193125-26-340159.md) | [3,574](/filings/0001193125-26-340159.md) | [3,652](/filings/0001193125-26-340159.md) | [4,521](/filings/0001193125-25-272134.md) | [5,724](/filings/0001193125-26-340159.md) | [6,186](/filings/0001193125-26-340159.md) | [4,565](/filings/0001193125-26-340159.md) |

- Cash and equivalents: us-gaap:Cash
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [21.4 d](/filings/0001193125-24-261004.md) | [(52.8) d](/filings/0001193125-26-077441.md) | [(721)](/filings/0001193125-25-116684.md) | [(137) d](/filings/0001193125-25-176892.md) | [(208) d](/filings/0001193125-25-272134.md) | [1,274 d](/filings/0001193125-26-077441.md) | [(719)](/filings/0001193125-26-214433.md) | [1,496 d](/filings/0001193125-26-340159.md) | [(2,048) d](/filings/0001193125-25-272134.md) | [1,025 d](/filings/0001193125-26-077441.md) | [(1,243)](/filings/0001193125-26-214433.md) | [(260) d](/filings/0001193125-26-340159.md) |
| Share repurchases | $m | [2,257 d](/filings/0001193125-24-261004.md) | [1,869 d](/filings/0001193125-26-077441.md) | [1,790](/filings/0001193125-25-116684.md) | [1,799 d](/filings/0001193125-25-176892.md) | [2,400 d](/filings/0001193125-25-272134.md) | [2,795 d](/filings/0001193125-26-077441.md) | [3,189](/filings/0001193125-26-214433.md) | [4,138 d](/filings/0001193125-26-340159.md) | [2,177 d](/filings/0001193125-25-272134.md) | [3,495 d](/filings/0001193125-26-077441.md) | [8,223](/filings/0001193125-26-214433.md) | [5,005 d](/filings/0001193125-26-340159.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

Shares outstanding: 131,511,975 at 2026-08-05, from the cover of the [10-Q filed 2026-08-07](/filings/0001193125-26-340159.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.